topotecan has been researched along with Cystadenocarcinoma, Serous in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 11 (47.83) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Aghajanian, C; Banerjee, S; Berger, R; Boyd, AP; Christy-Bittel, J; Churruca, C; Cibula, D; Clamp, A; Coleman, RL; Colombo, N; Del Campo, JM; Drill, E; Grisham, RN; Hilpert, F; Kalbacher, E; Kristensen, G; Marth, C; Mirza, MR; Monk, BJ; Moore, KN; O'Malley, DM; Oehler, MK; Oza, AM; Pignata, S; Ray-Coquard, I; Romero, I; Sehouli, J; Vergote, I; Vuylsteke, P; Westermann, A | 1 |
| Brajanovski, N; Chan, KT; Cullinane, C; Ellis, S; Hannan, KM; Hannan, RD; Kang, J; Madhamshettiwar, PB; Pearson, RB; Sanij, E; Sheppard, KE; Simpson, KJ; Tancock, MRC; Xuan, J; Yan, S | 1 |
| Atlas, I; Barak, F; Berman, T; Bruchim, I; Levy, T; Meirovitz, M; Rosengarten, OS; Safra, T; Yachnin, A | 1 |
| Curtin, J; Downey, A; Edwards, S; Kwa, M; Muggia, F; Reich, E; Wallach, R | 1 |
| Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
| Fabbro, M; Gligorov, J; Lhommé, C; Lokiec, F; Lotz, JP; Pautier, P; Provent, S; Richard, S; Selle, F; Soares, DG; Viens, P | 1 |
| Fusco, N; Haba, P; Rodriguez, M; Rose, PG; Smrekar, M | 1 |
| Aoki, D; Fujiwara, K; Hatae, M; Hiura, M; Kamiura, S; Katsumata, N; Kigawa, J; Nakanishi, T; Noda, K; Ochiai, K; Sugiyama, T; Takehara, K | 1 |
| Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| Camporeale, A; Cormio, G; De Mitri, P; Gissi, F; Leone, L; Loizzi, V; Putignano, G; Selvaggi, L | 1 |
| Bookman, MA | 1 |
| Arcand, SL; Caceres, KY; Cyr, L; de Ladurantaye, M; Delvoye, N; Létourneau, IJ; Mes-Masson, AM; Meunier, L; Portelance, L; Provencher, DM; Quinn, MC; Shen, Z; Tonin, PN; Wang, LL | 1 |
| Aydin, F; Canturk, T; Senturk, N; Turanli, AY; Yanik, F; Yildiz, L | 1 |
| Berkowitz, R; Campos, S; Colella, T; Duska, L; Fuller, A; Gore, S; Lee, H; Matulonis, U; Roche, M; Seiden, MV | 1 |
| Asmar, L; Bailey, CL; Gordon, AN; Messing, MJ; Pippitt, CH; Savage, J; Street, DG; Young, JA | 1 |
| Bădulescu, A; Bădulescu, F; Popescu, CF; Schenker, M; Stoica, Z | 1 |
| Grønlund, B | 1 |
| Corrado, G; Samaritani, R; Sbiroli, C; Vizza, E | 1 |
| Chen, TT; Escalon, J; Hills, D; Hochster, H; Ivy, P; Liebes, L; Lu, JM; Muggia, F; Sorich, J | 1 |
| Cui, BX; Jiang, J; Kong, BH; Meng, LH; Su, SL; Wang, B; Wang, LJ; Yang, XS; Zhang, YZ | 1 |
| Chamorey, E; Creisson, A; Ferrero, JM; Hebert, C; Largillier, R; Lesbats, G; Mari, V; Novo, C; Valenza, B | 1 |
| Malik, IA | 1 |
| Shen, K; Sun, Z; Xu, X | 1 |
2 review(s) available for topotecan and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Denmark; Diagnostic Imaging; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topotecan; Treatment Outcome | 2006 |
10 trial(s) available for topotecan and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Topics: Adult; Aged; Benzimidazoles; Cystadenocarcinoma, Serous; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Protein Kinase Inhibitors; Topotecan; Young Adult | 2020 |
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Israel; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Topotecan | 2013 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Salvage Therapy; Survival Rate; Topotecan; Young Adult | 2016 |
A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Prognosis; Survival Rate; Topotecan | 2008 |
A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Cohort Studies; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Salvage Therapy; Survival Rate; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan | 2011 |
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2003 |
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2004 |
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Topotecan; Treatment Outcome | 2008 |
[Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Topotecan; Treatment Outcome | 2007 |
11 other study(ies) available for topotecan and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; DNA Damage; DNA Replication; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Female; G1 Phase Cell Cycle Checkpoints; Genes, BRCA2; Homologous Recombination; Humans; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred NOD; Mice, SCID; Naphthyridines; Neoplasm Grading; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; RNA Interference; RNA Polymerase I; Topoisomerase I Inhibitors; Topotecan | 2021 |
Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cystadenocarcinoma, Serous; Etoposide; Female; Floxuridine; Follow-Up Studies; Heterozygote; Humans; Injections, Intraperitoneal; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Survival Rate; Topotecan | 2014 |
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan | 2010 |
Long-term topotecan therapy in recurrent or persistent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Disease Progression; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2011 |
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, SCID; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Topotecan-induced celluitis-like fixed drug eruption.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cellulitis; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Eruptions; Fatal Outcome; Female; Humans; Hysterectomy; Infusions, Intravenous; Leg Dermatoses; Ovarian Neoplasms; Ovariectomy; Risk Assessment; Topotecan | 2002 |
The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Topics: CA-125 Antigen; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan; Treatment Outcome | 2005 |
Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Colostomy; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Epoetin Alfa; Erythropoietin; Fatal Outcome; Female; Follow-Up Studies; Hemorrhage; Humans; Intestinal Obstruction; Karnofsky Performance Status; Laparotomy; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Peritoneal Neoplasms; Recombinant Proteins; Salvage Therapy; Topotecan; Urinary Bladder Neoplasms; Vitamins | 2007 |
Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Retrospective Studies; Survival Rate; Topotecan; Treatment Outcome | 2007 |
Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prospective Studies; Topotecan | 2001 |
[The effect of hydroxycamptothecin and topotecan to SKOV3 and CAOV3 in vitro].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured | 1999 |